Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hetastarch
Drug ID BADD_D01066
Description Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
Indications and Usage An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB09106
KEGG ID D03335
MeSH ID D006895
PubChem ID 24846132
TTD Drug ID Not Available
NDC Product Code 0409-1555; 18124-009; 0409-7248
UNII 875Y4127EA
Synonyms Hydroxyethyl Starch Derivatives | Derivatives, Hydroxyethyl Starch | Starch Derivatives, Hydroxyethyl | Hydroxyethylated Starches | Starches, Hydroxyethylated | Starches, 2-Hydroxyethyl | 2-Hydroxyethyl Starches | Starches, 2 Hydroxyethyl | Hemohes | Elohes | Hespan | Hetastarch | Pentafraction | Pentaspan | Pentastarch | Plasmasteril | HAES-steril | Hydroxyethyl Starch 130-0.4 | Hydroxyethyl Starch 130 0.4 | Hydroxyethyl Starch (130 KD-0.4 Substitution)
Chemical Information
Molecular Formula C29H52O21
CAS Registry Number 9004-62-0
SMILES CC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)OC)O)O)OC4C(C(C(C(O4)CO)OC)O)OC CO)O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metabolic acidosis14.01.01.003---
Myalgia15.05.02.001--
Non-cardiogenic pulmonary oedema22.01.03.006; 24.03.08.004---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Pancreatitis07.18.01.001--
Parotid gland enlargement07.06.03.001---
Periorbital oedema06.08.03.017; 10.01.05.010; 23.04.01.002--
Pruritus23.03.12.001--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Restlessness17.02.05.021; 19.11.02.002--
Sepsis11.01.11.003--
Skin disorder23.03.03.007---
Sneezing22.12.03.024--
Stridor22.04.02.003--
Submaxillary gland enlargement07.06.03.003---
Tachycardia02.03.02.007---
Tachypnoea22.02.01.014---
Urticaria10.01.06.001; 23.04.02.001--
Ventricular fibrillation02.03.04.008--
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Lymphatic disorder01.09.01.003---
Musculoskeletal discomfort15.03.04.001---
Haemorrhage24.07.01.002---
Blood disorder01.05.01.004---
Transfusion-related circulatory overload02.05.04.016; 12.02.08.006---
Acquired Von Willebrand's disease01.01.01.004---
Brief resolved unexplained event17.02.05.066; 18.04.15.006; 22.11.02.012---
The 2th Page    First    Pre   2    Total 2 Pages